Triall's open clinical trial platform leverages blockchain for secure data management, but its patient data de-identification algorithm may have vulnerabilities. Potential risks include insufficient anonymization, where quasi-identifiers like age or medical history could enable re-identification when cross-referenced with external datasets. Weak pseudonymization methods, such as predictable codes, may also increase re-identification risks. Additionally, blockchain's immutability could complicate data erasure under GDPR’s “right to be forgotten.” To mitigate these, Triall should adopt robust techniques like k-anonymity, suppress unique identifiers, and implement secure data-sharing agreements. Regular audits and adherence to HIPAA and GDPR standards are critical to ensure patient privacy while maintaining data utility for research.